Logo image of CSCW

COLOR STAR TECHNOLOGY CO LTD (CSCW) Stock Fundamental Analysis

NASDAQ:CSCW - Nasdaq - KYG2287A2093 - Common Stock - Currency: USD

1.08  -0.04 (-3.57%)

After market: 1.09 +0.01 (+0.93%)

Fundamental Rating

2

Taking everything into account, CSCW scores 2 out of 10 in our fundamental rating. CSCW was compared to 283 industry peers in the Software industry. While CSCW seems to be doing ok healthwise, there are quite some concerns on its profitability. CSCW does not seem to be growing, but still is valued expensively.


Dividend Valuation Growth Profitability Health

0

1. Profitability

1.1 Basic Checks

CSCW had negative earnings in the past year.
CSCW had a negative operating cash flow in the past year.
CSCW Yearly Net Income VS EBIT VS OCF VS FCFCSCW Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 0 -20M -40M -60M

1.2 Ratios

Industry RankSector Rank
ROA -8.14%
ROE N/A
ROIC N/A
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
CSCW Yearly ROA, ROE, ROICCSCW Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 -500 -1K -1.5K -2K -2.5K

1.3 Margins

Industry RankSector Rank
OM -140.86%
PM (TTM) -121.44%
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
CSCW Yearly Profit, Operating, Gross MarginsCSCW Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 0 -50 -100

6

2. Health

2.1 Basic Checks

CSCW does not have a ROIC to compare to the WACC, probably because it is not profitable.
Compared to 1 year ago, CSCW has less shares outstanding
There is no outstanding debt for CSCW. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
CSCW Yearly Shares OutstandingCSCW Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 5M 10M 15M 20M 25M
CSCW Yearly Total Debt VS Total AssetsCSCW Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 20M 40M 60M 80M 100M

2.2 Solvency

Based on the Altman-Z score of 0.16, we must say that CSCW is in the distress zone and has some risk of bankruptcy.
There is no outstanding debt for CSCW. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z 0.16
ROIC/WACCN/A
WACC10.94%
CSCW Yearly LT Debt VS Equity VS FCFCSCW Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 0 50M -50M

2.3 Liquidity

CSCW has a Current Ratio of 12.12. This indicates that CSCW is financially healthy and has no problem in meeting its short term obligations.
CSCW has a Quick Ratio of 12.12. This indicates that CSCW is financially healthy and has no problem in meeting its short term obligations.
Industry RankSector Rank
Current Ratio 12.12
Quick Ratio 12.12
CSCW Yearly Current Assets VS Current LiabilitesCSCW Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 20M 40M 60M 80M 100M

0

3. Growth

3.1 Past

CSCW shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -383.94%.
CSCW shows a very negative growth in Revenue. Measured over the last years, the Revenue has been decreasing by -33.88% yearly.
EPS 1Y (TTM)-383.94%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%96.27%
Revenue 1Y (TTM)N/A
Revenue growth 3Y-47.05%
Revenue growth 5Y-33.88%
Sales Q2Q%304.74%

3.2 Future

No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next YN/A
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
CSCW Yearly Revenue VS EstimatesCSCW Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 10M 20M 30M 40M 50M
CSCW Yearly EPS VS EstimatesCSCW Yearly EPS VS EstimatesYearly EPS VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021

0

4. Valuation

4.1 Price/Earnings Ratio

CSCW reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
CSCW Price Earnings VS Forward Price EarningsCSCW Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 0 0 0 0 0 0 0 0 0 0

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA 1.12
CSCW Per share dataCSCW EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 10 -10 20

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2YN/A
EPS Next 3YN/A

0

5. Dividend

5.1 Amount

No dividends for CSCW!.
Industry RankSector Rank
Dividend Yield N/A

COLOR STAR TECHNOLOGY CO LTD

NASDAQ:CSCW (10/31/2022, 8:11:55 PM)

After market: 1.09 +0.01 (+0.93%)

1.08

-0.04 (-3.57%)

Chartmill FA Rating
GICS SectorInformation Technology
GICS IndustryGroupSoftware & Services
GICS IndustrySoftware
Earnings (Last)11-02 2022-11-02/bmo
Earnings (Next)11-22 2022-11-22/bmo
Inst Owners0.27%
Inst Owner Change-97.68%
Ins OwnersN/A
Ins Owner ChangeN/A
Market Cap3.94M
Analysts0
Price TargetN/A
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DP0%
Div Incr YearsN/A
Div Non Decr YearsN/A
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)N/A
PT rev (3m)N/A
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)N/A
EPS NY rev (3m)N/A
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 0.58
P/FCF N/A
P/OCF N/A
P/B 0.04
P/tB 0.05
EV/EBITDA 1.12
EPS(TTM)-4.84
EYN/A
EPS(NY)N/A
Fwd EYN/A
FCF(TTM)-19.17
FCFYN/A
OCF(TTM)-1.41
OCFYN/A
SpS1.86
BVpS27.14
TBVpS23.12
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -8.14%
ROE N/A
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM -140.86%
PM (TTM) -121.44%
GM N/A
FCFM N/A
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score5
Asset Turnover0.07
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 1071.94%
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 12.12
Quick Ratio 12.12
Altman-Z 0.16
F-Score5
WACC10.94%
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-383.94%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%96.27%
EPS Next YN/A
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)N/A
Revenue growth 3Y-47.05%
Revenue growth 5Y-33.88%
Sales Q2Q%304.74%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1YN/A
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y-1435.84%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-10.39%
OCF growth 3YN/A
OCF growth 5YN/A